Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00374049 · ClinicalTrials.gov registry record · Phase 1
MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer
A Phase 1 study, sponsored by Olivera Finn.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00374049 is a Phase 1 study that has completed, run by Olivera Finn. The registered enrollment target is 14 participants.
The verdict
NCT00374049, a Phase 1 study, has completed, sponsored by Olivera Finn.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness of a drug called Poly-ICLC, also known as HiltonolTM, in boosting the body's immune system's response to an experimental vaccine therapy (called the MUC-1 vaccine).
Interventions
- DRUG MUC_1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2006-06 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00374049
The ClinicalTrials.gov registry entry for NCT00374049 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Olivera Finn, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MUC_1 is the first listed.
NCT00374049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00374049 about?
NCT00374049 is a clinical study titled "MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer". The purpose of this study is to determine the effectiveness of a drug called Poly-ICLC, also known as HiltonolTM, in boosting the body's immune system's response to an experimental vaccine therapy (called the MUC-1 vaccine).
What is the current status of trial NCT00374049?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2006-06. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00374049?
The interventions under investigation include: MUC_1 (DRUG).
Who is sponsoring clinical trial NCT00374049?
This trial is sponsored by Olivera Finn, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.